Stanislav Hloušek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stanislav Hloušek has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Soňa Argalácsová
Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic
2 shared publications - David Hoskovec
1st Department of Surgery, General University Hospital in Prague and First Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic
1 shared publication - Jakub Tesař
1st Department of Surgery, General University Hospital in Prague and First Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic
1 shared publication - Jan Spacek
Department of Oncology, First Faculty of Medicine, General University Hospital in Prague, Charles University, 12808 Prague, Czech Republic
1 shared publication Jana Soukupová
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
1 shared publicationMarek Jurok
Department of Urology, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic
1 shared publication
Latest Publications
- Open Access
Prognostic Value of Hematologic Indices and Composite Models in Anal Squamous Cell Carcinoma Treated with Image-Guided Chemoradiotherapy
Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy primarily treated with chemoradiotherapy (CRT). This study evaluated outcomes and the prognostic value of simple hematologic indices in patients receiving modern image-guided CRT. Methods: Fifty-five patients with non-metastatic ASCC treated between 2017 and 2025 were retrospectively analyzed. Survival was estimated by Kaplan–Meier methods, and prognostic factors were assessed by log-rank testing and Cox regression. Baseline neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios were analyzed individually and in combination with nodal status. Results: At a median follow-up of 53.1 months, overall survival reached 90% at 5 years, whereas disease-free survival declined to 51%. Nodal positivity showed a non-significant trend toward poorer DFS. Baseline PLR ≥ 150 was significantly associated with inferior DFS in univariable analysis (HR 5.28, 95% CI 1.12–24.97, p = 0.036), while NLR ≥ 3 showed a borderline effect (p = 0.108). In multivariable models, PLR retained borderline prognostic relevance (p = 0.083), whereas Kaplan–Meier curves indicated non-significant trends (p = 0.129 and 0.055). Integrated models combining nodal status with PLR ± NLR improved risk discrimination: Model A (N + PLR ≥ 150 ± NLR ≥ 3) showed a trend (p = 0.059), and Model B (N + PLR ≥ 150) reached significance (p = 0.021; C-index ≈ 0.68–0.69). Conclusions: Modern CRT achieved excellent OS with acceptable toxicity, though early recurrences limited DFS. Integrating hematologic indices with nodal status provides a pragmatic, cost-effective approach for individualized risk assessment and follow-up in ASCC.
Open AccessPrognostic Value of Hematologic Indices and Composite Models in Anal Squamous Cell Carcinoma Treated with Image-Guided Chemoradiotherapy
Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy primarily treated with chemoradiotherapy (CRT). This study evaluated outcomes and the prognostic value of simple hematologic indices in patients receiving modern image-guided CRT. Methods: Fifty-five patients with non-metastatic ASCC treated between 2017 and 2025 were retrospectively analyzed. Survival was estimated by Kaplan–Meier methods, and prognostic factors were assessed by log-rank testing and Cox regression. Baseline neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios were analyzed individually and in combination with nodal status. Results: At a median follow-up of 53.1 months, overall survival reached 90% at 5 years, whereas disease-free survival declined to 51%. Nodal positivity showed a non-significant trend toward poorer DFS. Baseline PLR ≥ 150 was significantly associated with inferior DFS in univariable analysis (HR 5.28, 95% CI 1.12–24.97, p = 0.036), while NLR ≥ 3 showed a borderline effect (p = 0.108). In multivariable models, PLR retained borderline prognostic relevance (p = 0.083), whereas Kaplan–Meier curves indicated non-significant trends (p = 0.129 and 0.055). Integrated models combining nodal status with PLR ± NLR improved risk discrimination: Model A (N + PLR ≥ 150 ± NLR ≥ 3) showed a trend (p = 0.059), and Model B (N + PLR ≥ 150) reached significance (p = 0.021; C-index ≈ 0.68–0.69). Conclusions: Modern CRT achieved excellent OS with acceptable toxicity, though early recurrences limited DFS. Integrating hematologic indices with nodal status provides a pragmatic, cost-effective approach for individualized risk assessment and follow-up in ASCC.
- Open Access
- 30 October 2025
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 71 (3) , 95-108
Genetic and Non-Genetic Risk Factors in Prostate Cancer: Towards a Precision Medicine Approach
Prostate cancer (PCa) represents the most common malignancy among men in many countries, including the Czech Republic. While most cases are sporadic, approximately 10 % are attributed to hereditary factors, particularly germline pathogenic variants in genes such as BRCA1 and BRCA2 , ATM , and CHEK2 . These variants are associated with higher disease susceptibility, aggressive tumour behaviour and earlier onset of the disease. In parallel, modifiable and non-modifiable risk factors – including age, ethnicity, lifestyle, obesity, exposure to environmental carcinogens – also play an important role in the development and progression of PCa. This review summarizes the current state of knowledge on both genetic and non-genetic risk factors for PCa and emphasizes their relevance for clinical risk stratification, early detection strategies and prevention. The paper also provides an overview of the implications of hereditary PCa in the context of targeted therapy, particularly PARP inhibitors and immunotherapy, and discusses how somatic tumour profiling may refine the therapeutic decision-making. By integrating epidemiological data, molecular diagnostic and recent clinical advances, this review enhances understanding of the genetic underpinnings of PCa and advocates for a comprehensive, precision medicine approach in PCa management. The review emphasizes the importance of early identification of high-risk individuals through germline genetic testing and polygenic risk assessment, which can guide screening and personalized treatment and ultimately improve patient outcomes.
- 30 October 2025
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 71 (3) , 95-108
Open AccessGenetic and Non-Genetic Risk Factors in Prostate Cancer: Towards a Precision Medicine Approach
Prostate cancer (PCa) represents the most common malignancy among men in many countries, including the Czech Republic. While most cases are sporadic, approximately 10 % are attributed to hereditary factors, particularly germline pathogenic variants in genes such as BRCA1 and BRCA2 , ATM , and CHEK2 . These variants are associated with higher disease susceptibility, aggressive tumour behaviour and earlier onset of the disease. In parallel, modifiable and non-modifiable risk factors – including age, ethnicity, lifestyle, obesity, exposure to environmental carcinogens – also play an important role in the development and progression of PCa. This review summarizes the current state of knowledge on both genetic and non-genetic risk factors for PCa and emphasizes their relevance for clinical risk stratification, early detection strategies and prevention. The paper also provides an overview of the implications of hereditary PCa in the context of targeted therapy, particularly PARP inhibitors and immunotherapy, and discusses how somatic tumour profiling may refine the therapeutic decision-making. By integrating epidemiological data, molecular diagnostic and recent clinical advances, this review enhances understanding of the genetic underpinnings of PCa and advocates for a comprehensive, precision medicine approach in PCa management. The review emphasizes the importance of early identification of high-risk individuals through germline genetic testing and polygenic risk assessment, which can guide screening and personalized treatment and ultimately improve patient outcomes.